Rep. Weiss letter to FDA
Rep. Weiss (D-NY) has reportedly requested information from FDA pertaining to the approval of Burroughs Wellcome's Wellbutrin (buproprion), Pfizer's Feldene (piroxicam), and Hoechst Roussel's Merital (nomifensine). Sen. Heinz (R-Pa.) recently requested information on FDA's process of regulating Rx drugs, particularly with regard to Merital ("The Pink Sheet" Feb. 10, T&G-8).
You may also be interested in...
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.